We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sol-Gel Signs $27 M Deal for Dermatology Drug Delivery
News

Sol-Gel Signs $27 M Deal for Dermatology Drug Delivery

Sol-Gel Signs $27 M Deal for Dermatology Drug Delivery
News

Sol-Gel Signs $27 M Deal for Dermatology Drug Delivery

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sol-Gel Signs $27 M Deal for Dermatology Drug Delivery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Sol-Gel Technologies Ltd. has announced that it has entered into a second development and licensing agreement with a leading U.S. pharmaceutical company for the development and commercialization in the U.S. and Canada of a major dermatologic drug.

Under the terms of the new agreement, Sol-Gel will receive $27 million, comprised of an initial non-refundable payment as well as additional license fees and development payments upon the successful completion of various milestones.

The U.S. partner will fund the product’s development. Sol-Gel will be entitled to receive royalties from net sales.

The new agreement follows a similar $25 million deal made with the same company.

“This repeat collaboration reinforces Sol-Gel’s position as a leading player in the development of encapsulation technologies for application to topical drug products,” said Dr. Alon Seri-Levy, co-founder and CEO.

Advertisement